CARsgen Therapeutics Holdings Ltd
HKEX:2171

Watchlist Manager
CARsgen Therapeutics Holdings Ltd Logo
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Watchlist
Price: 8.36 HKD -0.71% Market Closed
Market Cap: 4.8B HKD
Have any thoughts about
CARsgen Therapeutics Holdings Ltd?
Write Note

CARsgen Therapeutics Holdings Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CARsgen Therapeutics Holdings Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Revenue
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
ÂĄ17.4B
CAGR 3-Years
102%
CAGR 5-Years
68%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Revenue
ÂĄ7.5B
CAGR 3-Years
16%
CAGR 5-Years
84%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
ÂĄ5.5B
CAGR 3-Years
33%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Revenue
ÂĄ36.4B
CAGR 3-Years
12%
CAGR 5-Years
31%
CAGR 10-Years
47%
Imeik Technology Development Co Ltd
SZSE:300896
Revenue
ÂĄ2.9B
CAGR 3-Years
59%
CAGR 5-Years
55%
CAGR 10-Years
N/A
No Stocks Found

CARsgen Therapeutics Holdings Ltd
Glance View

Market Cap
4.8B HKD
Industry
Biotechnology

CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.

Intrinsic Value
12.81 HKD
Undervaluation 35%
Intrinsic Value
Price

See Also

What is CARsgen Therapeutics Holdings Ltd's Revenue?
Revenue
0 CNY

Based on the financial report for Dec 31, 2023, CARsgen Therapeutics Holdings Ltd's Revenue amounts to 0 CNY.

Back to Top